Since its inception in 2000, Cyclopharma plays a key role in the development of Molecular Imaging. Specialized in the development and marketing of radiotracers, Cyclopharma grew by more than 40% per year on average.
In 2013, Cyclopharma joins Denos, a French company specialized in international heathcare services, with a new twofold ambition : develop new molecules for personalized medicine and grow on international markets.
Since 2014, Cyclopharma’s R&D budget has doubled and now represents more than 10% of revenues, to research, develop and market one innovative molecule per year until 2020.
They support us